Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 146

1.
2.

Changes and relations of circulating visfatin, apelin, and resistin levels in normal, impaired glucose tolerance, and type 2 diabetic subjects.

Li L, Yang G, Li Q, Tang Y, Yang M, Yang H, Li K.

Exp Clin Endocrinol Diabetes. 2006 Nov;114(10):544-8.

PMID:
17177135
3.

Adipokines in type 1 diabetes after successful pancreas transplantation: normal visfatin and retinol-binding-protein-4, but increased total adiponectin fasting concentrations.

Stadler M, Storka A, Theuer EA, Krebs M, Vojtassakova E, Nowotny P, Pacini G, Kästenbauer T, Luger A, Prager R, Wolzt M, Anderwald C.

Clin Endocrinol (Oxf). 2010 Jun;72(6):763-9. doi: 10.1111/j.1365-2265.2009.03709.x. Epub 2009 Sep 21.

PMID:
19769621
4.

Maternal and cord blood apelin, resistin and visfatin levels in gestational diabetes mellitus.

Oncul M, Tuten A, Erman H, Gelisgen R, Benian A, Uzun H.

Minerva Med. 2013 Oct;104(5):527-35.

PMID:
24101110
5.

Apelin, vaspin, visfatin and adiponectin in large for gestational age infants with insulin resistance.

Cekmez F, Canpolat FE, Pirgon O, Çetinkaya M, Aydinoz S, Suleymanoglu S, Ipcioglu OM, Sarici SU.

Cytokine. 2011 Nov;56(2):387-91. doi: 10.1016/j.cyto.2011.06.007. Epub 2011 Jul 13.

PMID:
21742512
6.

Apelin levels are increased in morbidly obese subjects with type 2 diabetes mellitus.

Soriguer F, Garrido-Sanchez L, Garcia-Serrano S, Garcia-Almeida JM, Garcia-Arnes J, Tinahones FJ, Garcia-Fuentes E.

Obes Surg. 2009 Nov;19(11):1574-80. doi: 10.1007/s11695-009-9955-y. Epub 2009 Sep 15.

PMID:
19756893
7.

Effects of atorvastatin on apelin, visfatin (nampt), ghrelin and early carotid atherosclerosis in patients with type 2 diabetes.

Kadoglou NP, Sailer N, Kapelouzou A, Lampropoulos S, Vitta I, Kostakis A, Liapis CD.

Acta Diabetol. 2012 Aug;49(4):269-76. doi: 10.1007/s00592-011-0310-0. Epub 2011 Jul 12.

PMID:
21748474
8.

Effects of rosiglitazone and metformin treatment on apelin, visfatin, and ghrelin levels in patients with type 2 diabetes mellitus.

Kadoglou NP, Tsanikidis H, Kapelouzou A, Vrabas I, Vitta I, Karayannacos PE, Liapis CD, Sailer N.

Metabolism. 2010 Mar;59(3):373-9. doi: 10.1016/j.metabol.2009.08.005. Epub 2009 Oct 7.

PMID:
19815243
9.

Low plasma apelin levels in newly diagnosed type 2 diabetes mellitus.

Erdem G, Dogru T, Tasci I, Sonmez A, Tapan S.

Exp Clin Endocrinol Diabetes. 2008 May;116(5):289-92. doi: 10.1055/s-2007-1004564.

PMID:
18484561
10.

Serum visfatin levels, adiposity and glucose metabolism in obese adolescents.

Taşkesen D, Kirel B, Us T.

J Clin Res Pediatr Endocrinol. 2012 Jun;4(2):76-81. doi: 10.4274/jcrpe.547.

11.

Plasma visfatin concentrations in subjects with type 1 diabetes mellitus.

Toruner F, Altinova AE, Bukan N, Arslan E, Akbay E, Ersoy R, Arslan M.

Horm Res. 2009;72(1):33-7. doi: 10.1159/000224338. Epub 2009 Jun 30.

PMID:
19571557
12.

Visfatin levels do not change after the oral glucose tolerance test and after a dexamethasone-induced increase in insulin resistance in humans.

Marcinkowska M, Lewandowski KC, Lewiński A, Bieńkiewicz M, Basińska-Lewandowska M, Salata I, Randeva HS.

Endokrynol Pol. 2007 May-Jun;58(3):188-94.

PMID:
17940983
13.

[Association between both resistin, visfatin and insulin resistance as well as β cell function in the first-degree relatives of type 2 diabetes mellitus].

Zhang XJ, Wang Z, Li HH, Yu L, Gao S.

Zhonghua Liu Xing Bing Xue Za Zhi. 2010 Dec;31(12):1393-6. Chinese.

PMID:
21223671
14.

Elevated plasma levels of apelin in children with type 1 diabetes mellitus.

Meral C, Tascilar E, Karademir F, Tanju IA, Cekmez F, Ipcioglu OM, Ercin CN, Gocmen I, Dogru T.

J Pediatr Endocrinol Metab. 2010 May;23(5):497-502.

PMID:
20662349
15.

Plasma visfatin levels in patients with newly diagnosed and untreated type 2 diabetes mellitus and impaired glucose tolerance.

Dogru T, Sonmez A, Tasci I, Bozoglu E, Yilmaz MI, Genc H, Erdem G, Gok M, Bingol N, Kilic S, Ozgurtas T, Bingol S.

Diabetes Res Clin Pract. 2007 Apr;76(1):24-9. Epub 2006 Sep 7.

PMID:
16956691
16.

Intensive glycemic control lowers plasma visfatin levels in patients with type 2 diabetes.

Zhu J, Schott M, Liu R, Liu C, Shen B, Wang Q, Mao X, Xu K, Wu X, Schinner S, Papewalis C, Scherbaum WA, Liu C.

Horm Metab Res. 2008 Nov;40(11):801-5. doi: 10.1055/s-0028-1082040. Epub 2008 Aug 6.

PMID:
18686225
17.

Report of the Committee on the classification and diagnostic criteria of diabetes mellitus.

Kuzuya T, Nakagawa S, Satoh J, Kanazawa Y, Iwamoto Y, Kobayashi M, Nanjo K, Sasaki A, Seino Y, Ito C, Shima K, Nonaka K, Kadowaki T; Committee of the Japan Diabetes Society on the diagnostic criteria of diabetes mellitus.

Diabetes Res Clin Pract. 2002 Jan;55(1):65-85.

PMID:
11755481
18.

Serum visfatin in Asian women with polycystic ovary syndrome.

Jongwutiwes T, Lertvikool S, Leelaphiwat S, Rattanasiri S, Jultanmas R, Weerakiet S.

Gynecol Endocrinol. 2009 Aug;25(8):536-42. doi: 10.1080/09513590903015478.

PMID:
19533482
19.

The differential anti-inflammatory effects of exercise modalities and their association with early carotid atherosclerosis progression in patients with type 2 diabetes.

Kadoglou NP, Fotiadis G, Kapelouzou A, Kostakis A, Liapis CD, Vrabas IS.

Diabet Med. 2013 Feb;30(2):e41-50. doi: 10.1111/dme.12055.

PMID:
23078531
20.

Acute and chronic effects of biliopancreatic diversion with duodenal switch surgery on plasma visfatin and apelin levels in patients with severe obesity.

Caron-Cantin SM, Martin J, Bastien M, Munkonda MN, Lu H, Cianflone K, Moustarah F, Biertho L, Marceau S, Hould FS, Bussières J, Poirier P.

Obes Surg. 2013 Nov;23(11):1806-14. doi: 10.1007/s11695-013-0952-9.

PMID:
23585024

Supplemental Content

Support Center